Huons Global announced that Huons Group Chairman Yoon Sung-tae has returned to management, as approved at the annual general meeting of shareholders and the board meeting in Pangyo, Seongnam, on Friday.

The company, the holding entity of Huons Group, stated that all agenda items were passed at the meeting. At the meeting, shareholders approved all agenda items, including:

ㆍApproval of financial statements for the 38th term and cash dividends of 250 won per share

ㆍAmendments to the articles of incorporation

ㆍReduction of capital reserves

ㆍAppointment of one inside director (Song Soo-young) and one outside director (Han Seung-beom)

ㆍAppointment of outside director Lee Kyu-yeon as an audit committee member

ㆍAppointment of Han Seung-beom as an audit committee member

ㆍSetting the remuneration cap for directors

Following the shareholder meeting, the board appointed Chairman Yoon as CEO of Huons Global, making him co-CEO alongside Song Soo-young.

Yoon’s return to leadership comes three years after stepping down as Huons Global CEO in 2022. As CEO of the holding company, he will now focus on driving the group’s future growth, navigating economic challenges, strengthening core competencies, expanding global operations, and securing competitive new pipelines.

“Despite ongoing internal and external uncertainties, 2025 will be a year of great progress for Huons Group as we celebrate our 60th anniversary,” Yoon said. “I plan to focus on key strategic initiatives, including global expansion and securing new growth engines through research and development.”

In 2024, Huons Global posted record revenue of 813.5 billion won ($554.5 million), a 7.3 percent increase year-on-year, while operating profit declined 14.9 percent to 97 billion won.

Huons Group operates five Kosdaq-listed companies—Huons Global (the holding company), Huons, Humedix, HuM&C, and Pangen Biotech—alongside nine subsidiaries and affiliates. Biopharmaceutical company Pangen Biotech became a Huons affiliate in December 2024.